Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.

Cancer chemotherapy and pharmacology - 1 Nov 2011

Park In Hae, Lee Yeon-Su, Lee Keun Seok, Kim Sook-young, Hong Seung-Hyun, Jeong Jaeheon, Lee Hyewon, Ro Jungsil, Nam Byung-Ho

Abstract excerpt

PURPOSE: The CYP19A1 gene encodes the aromatase enzyme involved in the peripheral conversion of androgen to estrogen. We evaluated the efficacy of the aromatase inhibitor letrozole in patients with metastatic breast cancer (MBC) as related to DNA polymorphisms of CYP19A1. PATIENTS AND METHODS: One hundred and nine patients with hormone receptor-positive MBC were treated with letrozole alone or in combination with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aromatase

Share to Breast Neoplasms

Share to Disease Progression

Share to Neoplasm Metastasis

Share to Nitriles

Share to Triazoles

Source

Identifiers

PMID: 21442439
DOI: 10.1007/s00280-011-1615-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.PMID 21442439Read ↗

Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.Semantic proximity Read ↗

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.Semantic proximity Read ↗

Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.Semantic proximity Read ↗

A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.Semantic proximity Read ↗

Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.Semantic proximity Read ↗

Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.Semantic proximity Read ↗

A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma.Semantic proximity Read ↗

Pharmacogenomics of third-generation aromatase inhibitors.Semantic proximity Read ↗

Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.Semantic proximity Read ↗

Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.Semantic proximity Read ↗

Significance of the Estrogen Hormone and Single Nucleotide Polymorphisms in the Progression of Breast Cancer among Female.Semantic proximity Read ↗

The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.